- Home
- HZO vs MYGN Comparison
HZO vs MYGN Comparison
Compare HZO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HZO
- MYGN
- Stock Information
- Founded
- HZO 1998
- MYGN 1991
- Country
- HZO United States
- MYGN United States
- Employees
- HZO N/A
- MYGN N/A
- Industry
- HZO Auto & Home Supply Stores
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HZO Consumer Discretionary
- MYGN Health Care
- Exchange
- HZO Nasdaq
- MYGN Nasdaq
- Market Cap
- HZO 604.0M
- MYGN 642.0M
- IPO Year
- HZO 1998
- MYGN 1995
- Fundamental
- Price
- HZO $26.82
- MYGN $8.10
- Analyst Decision
- HZO Strong Buy
- MYGN Hold
- Analyst Count
- HZO 4
- MYGN 13
- Target Price
- HZO $34.00
- MYGN $13.50
- AVG Volume (30 Days)
- HZO 410.3K
- MYGN 1.3M
- Earning Date
- HZO 10-30-2025
- MYGN 11-06-2025
- Dividend Yield
- HZO N/A
- MYGN N/A
- EPS Growth
- HZO N/A
- MYGN N/A
- EPS
- HZO N/A
- MYGN N/A
- Revenue
- HZO $2,320,257,000.00
- MYGN $832,900,000.00
- Revenue This Year
- HZO N/A
- MYGN $0.17
- Revenue Next Year
- HZO $3.85
- MYGN $5.99
- P/E Ratio
- HZO N/A
- MYGN N/A
- Revenue Growth
- HZO N/A
- MYGN 3.83
- 52 Week Low
- HZO $16.85
- MYGN $3.76
- 52 Week High
- HZO $35.46
- MYGN $25.25
- Technical
- Relative Strength Index (RSI)
- HZO 54.92
- MYGN 60.51
- Support Level
- HZO $23.45
- MYGN $7.34
- Resistance Level
- HZO $28.29
- MYGN $8.25
- Average True Range (ATR)
- HZO 1.25
- MYGN 0.43
- MACD
- HZO 0.03
- MYGN -0.04
- Stochastic Oscillator
- HZO 69.42
- MYGN 75.93
About HZO MarineMax Inc. (FL)
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.